Scotiabank raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $75 from $53 and keeps an Outperform rating on the shares. The firm increased its price target on the stock given the promising results presented for its phase 3 ENERGIZE-T study as well as its announcement it filed for the regulatory approval of mitapivat for the treatment of thalassemia in four regions, the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios presents results from Phase 3 ENERGIZE-T Study of Mitapivat
- Agios Pharmaceuticals to present new data on mitapivat, tebapivat
- Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank
- Agios Pharmaceuticals Reports Robust Q3 2024 Results
- Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11